Health Hope Pharma Collaborates with Gilead Sciences to Advance Encequidar in Virology

Shots: Health Hope Pharma (HHP) has entered into a global licensing & collaboration agreement with Gilead Sciences to advance encequidar in the field of virology As per the deal, Gilead will receive exclusive global virology rights to encequidar, while HHP & Hanmi Pharm will provide drug supply, technical support, project collaboration & receive an upfront…

ByRidhi RastogiSeptember 30, 2025

NEWS

Airiver Medical Receives the US FDA’s IDE Approval to Study Airiver Pulmonary Drug Coated Balloon for Benign Central Airway Stenosis

Shots: Airiver Medical has received the US FDA’s IDE approval to initiate trial for Airiver Pulmonary Drug Coated Balloon (DCB) for the treatment of central airway stenosis The study will assess safety & efficacy of Airiver Pulmonary DCB against SoC bare balloon dilation in ~200 pts with central airway stenosis & support the US FDA…

ByRidhi RastogiAugust 28, 2025

NEWS

Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study Evaluating Enhertu in HER2+ Metastatic Gastric Cancer Patients

Shots: The data from P-III (DESTINY-Gastric04) study showed statistically significant and clinically meaningful improvement in OS vs ramucirumab & paclitaxel in 2L HER2+ (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or GEJ adenocarcinoma pts. The safety profile observed in DESTINY-Gastric04 aligns with Enhertu's established safety record. The company expects to present data…

ByRidhi RastogiMarch 4, 2025

Health Hope Pharma Collaborates with Gilead Sciences to Advance Encequidar in Virology

Airiver Medical Receives the US FDA’s IDE Approval to Study Airiver Pulmonary Drug Coated Balloon for Benign Central Airway Stenosis

Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study Evaluating Enhertu in HER2+ Metastatic Gastric Cancer Patients

Contact US

OUR INFORMATION

FOLLOW US